Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SLP vs SCYX vs CRL vs ICLR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SLP
Simulations Plus, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$324M
5Y Perf.-68.3%
SCYX
SCYNEXIS, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$42M
5Y Perf.-87.3%
CRL
Charles River Laboratories International, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$8.98B
5Y Perf.+1.3%
ICLR
ICON Public Limited Company

Medical - Diagnostics & Research

HealthcareNASDAQ • IE
Market Cap$9.54B
5Y Perf.-25.8%

SLP vs SCYX vs CRL vs ICLR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SLP logoSLP
SCYX logoSCYX
CRL logoCRL
ICLR logoICLR
IndustryMedical - Healthcare Information ServicesDrug Manufacturers - Specialty & GenericMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$324M$42M$8.98B$9.54B
Revenue (TTM)$79M$21M$4.03B$8.10B
Net Income (TTM)$-64M$-9M$-185M$599M
Gross Margin59.6%9.5%24.9%26.9%
Operating Margin-89.2%-77.9%11.8%12.2%
Forward P/E18.0x16.4x10.5x
Total Debt$616K$2M$3.07B$3.60B
Cash & Equiv.$31M$21M$214M$539M

SLP vs SCYX vs CRL vs ICLRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SLP
SCYX
CRL
ICLR
StockMay 20May 26Return
Simulations Plus, I… (SLP)10031.7-68.3%
SCYNEXIS, Inc. (SCYX)10012.7-87.3%
Charles River Labor… (CRL)100101.3+1.3%
ICON Public Limited… (ICLR)10074.2-25.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: SLP vs SCYX vs CRL vs ICLR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ICLR leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. SCYNEXIS, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. CRL also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SLP
Simulations Plus, Inc.
The Income Pick

SLP is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 4 yrs, beta 1.25
  • Lower volatility, beta 1.25, Low D/E 0.5%, current ratio 7.67x
Best for: income & stability and sleep-well-at-night
SCYX
SCYNEXIS, Inc.
The Growth Play

SCYX is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.

  • Rev growth 449.9%, EPS growth 61.4%, 3Y rev CAGR 59.4%
  • Beta 0.78, current ratio 7.04x
  • 449.9% revenue growth vs CRL's -0.9%
  • Beta 0.78 vs ICLR's 1.60, lower leverage
Best for: growth exposure and defensive
CRL
Charles River Laboratories International, Inc.
The Long-Run Compounder

CRL is the clearest fit if your priority is long-term compounding.

  • 119.2% 10Y total return vs ICLR's 91.0%
  • +32.8% vs SLP's -44.6%
Best for: long-term compounding
ICLR
ICON Public Limited Company
The Value Play

ICLR carries the broadest edge in this set and is the clearest fit for value and quality.

  • Lower P/E (10.5x vs 16.4x)
  • 7.4% margin vs SLP's -81.7%
  • 3.6% ROA vs SLP's -46.6%, ROIC 6.5% vs -39.6%
Best for: value and quality
See the full category breakdown
CategoryWinnerWhy
GrowthSCYX logoSCYX449.9% revenue growth vs CRL's -0.9%
ValueICLR logoICLRLower P/E (10.5x vs 16.4x)
Quality / MarginsICLR logoICLR7.4% margin vs SLP's -81.7%
Stability / SafetySCYX logoSCYXBeta 0.78 vs ICLR's 1.60, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)CRL logoCRL+32.8% vs SLP's -44.6%
Efficiency (ROA)ICLR logoICLR3.6% ROA vs SLP's -46.6%, ROIC 6.5% vs -39.6%

SLP vs SCYX vs CRL vs ICLR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SLPSimulations Plus, Inc.
FY 2025
License and Maintenance
57.9%$46M
Service
42.1%$33M
SCYXSCYNEXIS, Inc.
FY 2025
License and Service
93.0%$19M
Product
7.0%$1M
CRLCharles River Laboratories International, Inc.
FY 2025
Discovery and Safety Assessment
59.8%$2.4B
Research Models and Services
21.1%$846M
Manufacturing Support
19.1%$766M
ICLRICON Public Limited Company
FY 2012
Clinical Research
92.2%$1.0B
Central Laboratory
7.8%$87M

SLP vs SCYX vs CRL vs ICLR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLICLRLAGGINGSCYX

Income & Cash Flow (Last 12 Months)

Evenly matched — SLP and SCYX and ICLR each lead in 2 of 6 comparable metrics.

ICLR is the larger business by revenue, generating $8.1B annually — 393.3x SCYX's $21M. ICLR is the more profitable business, keeping 7.4% of every revenue dollar as net income compared to SLP's -81.7%. On growth, SCYX holds the edge at +18.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSLP logoSLPSimulations Plus,…SCYX logoSCYXSCYNEXIS, Inc.CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
RevenueTrailing 12 months$79M$21M$4.0B$8.1B
EBITDAEarnings before interest/tax-$63M$11M$757M$1.4B
Net IncomeAfter-tax profit-$64M-$9M-$185M$599M
Free Cash FlowCash after capex$23M-$5M$391M$996M
Gross MarginGross profit ÷ Revenue+59.6%+9.5%+24.9%+26.9%
Operating MarginEBIT ÷ Revenue-89.2%-77.9%+11.8%+12.2%
Net MarginNet income ÷ Revenue-81.7%-41.8%-4.6%+7.4%
FCF MarginFCF ÷ Revenue+29.2%-25.6%+9.7%+12.3%
Rev. Growth (YoY)Latest quarter vs prior year-2.7%+18.1%+1.2%+0.6%
EPS Growth (YoY)Latest quarter vs prior year+2.3%+3.3%-160.0%-98.7%
Evenly matched — SLP and SCYX and ICLR each lead in 2 of 6 comparable metrics.

Valuation Metrics

ICLR leads this category, winning 4 of 6 comparable metrics.

On an enterprise value basis, ICLR's 7.9x EV/EBITDA is more attractive than CRL's 13.0x.

MetricSLP logoSLPSimulations Plus,…SCYX logoSCYXSCYNEXIS, Inc.CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
Market CapShares × price$324M$42M$9.0B$9.5B
Enterprise ValueMkt cap + debt − cash$293M$23M$11.8B$12.6B
Trailing P/EPrice ÷ TTM EPS-4.99x-5.63x-62.52x13.12x
Forward P/EPrice ÷ next-FY EPS est.18.01x16.42x10.53x
PEG RatioP/E ÷ EPS growth rate1.87x
EV / EBITDAEnterprise value multiple12.98x7.95x
Price / SalesMarket cap ÷ Revenue4.09x2.02x2.24x1.15x
Price / BookPrice ÷ Book value/share2.59x0.97x2.81x1.09x
Price / FCFMarket cap ÷ FCF18.58x17.31x8.53x
ICLR leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

ICLR leads this category, winning 4 of 9 comparable metrics.

ICLR delivers a 6.3% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-51 for SLP. SLP carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs CRL's 4/9, reflecting strong financial health.

MetricSLP logoSLPSimulations Plus,…SCYX logoSCYXSCYNEXIS, Inc.CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
ROE (TTM)Return on equity-50.5%-19.0%-5.7%+6.3%
ROA (TTM)Return on assets-46.6%-14.4%-2.5%+3.6%
ROICReturn on invested capital-39.6%-28.2%+6.3%+6.5%
ROCEReturn on capital employed-44.1%-26.8%+8.1%+7.8%
Piotroski ScoreFundamental quality 0–96547
Debt / EquityFinancial leverage0.00x0.04x0.95x0.38x
Net DebtTotal debt minus cash-$30M-$19M$2.9B$3.1B
Cash & Equiv.Liquid assets$31M$21M$214M$539M
Total DebtShort + long-term debt$616,000$2M$3.1B$3.6B
Interest CoverageEBIT ÷ Interest expense-20.98x6.38x3.96x
ICLR leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CRL leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ICLR five years ago would be worth $5,463 today (with dividends reinvested), compared to $1,393 for SCYX. Over the past 12 months, CRL leads with a +32.8% total return vs SLP's -44.6%. The 3-year compound annual growth rate (CAGR) favors CRL at -1.4% vs SCYX's -31.5% — a key indicator of consistent wealth creation.

MetricSLP logoSLPSimulations Plus,…SCYX logoSCYXSCYNEXIS, Inc.CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
YTD ReturnYear-to-date-11.3%+49.8%-10.1%-33.7%
1-Year ReturnPast 12 months-44.6%-0.4%+32.8%-10.0%
3-Year ReturnCumulative with dividends-59.6%-67.9%-4.2%-34.1%
5-Year ReturnCumulative with dividends-70.5%-86.1%-46.9%-45.4%
10-Year ReturnCumulative with dividends+104.0%-97.6%+119.2%+91.0%
CAGR (3Y)Annualised 3-year return-26.0%-31.5%-1.4%-13.0%
CRL leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SCYX and CRL each lead in 1 of 2 comparable metrics.

SCYX is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than ICLR's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRL currently trades 79.5% from its 52-week high vs SLP's 47.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSLP logoSLPSimulations Plus,…SCYX logoSCYXSCYNEXIS, Inc.CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
Beta (5Y)Sensitivity to S&P 5001.25x0.78x1.52x1.60x
52-Week HighHighest price in past year$34.01$1.31$228.88$211.00
52-Week LowLowest price in past year$11.09$0.56$131.30$66.57
% of 52W HighCurrent price vs 52-week peak+47.2%+73.1%+79.5%+59.2%
RSI (14)Momentum oscillator 0–10067.951.357.262.1
Avg Volume (50D)Average daily shares traded315K571K806K1.1M
Evenly matched — SCYX and CRL each lead in 1 of 2 comparable metrics.

Analyst Outlook

SLP leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SLP as "Buy", CRL as "Buy", ICLR as "Buy". Consensus price targets imply 248.7% upside for SLP (target: $56) vs 12.9% for CRL (target: $205).

MetricSLP logoSLPSimulations Plus,…SCYX logoSCYXSCYNEXIS, Inc.CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$56.00$205.43$149.63
# AnalystsCovering analysts83630
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises41
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+4.0%+5.2%
SLP leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ICLR leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). CRL leads in 1 (Total Returns). 2 tied.

Best OverallICON Public Limited Company (ICLR)Leads 2 of 6 categories
Loading custom metrics...

SLP vs SCYX vs CRL vs ICLR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SLP or SCYX or CRL or ICLR a better buy right now?

For growth investors, SCYNEXIS, Inc.

(SCYX) is the stronger pick with 449. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Simulations Plus, Inc. (SLP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SLP or SCYX or CRL or ICLR?

On forward P/E, ICON Public Limited Company is actually cheaper at 10.

5x.

03

Which is the better long-term investment — SLP or SCYX or CRL or ICLR?

Over the past 5 years, ICON Public Limited Company (ICLR) delivered a total return of -45.

4%, compared to -86. 1% for SCYNEXIS, Inc. (SCYX). Over 10 years, the gap is even starker: CRL returned +119. 2% versus SCYX's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SLP or SCYX or CRL or ICLR?

By beta (market sensitivity over 5 years), SCYNEXIS, Inc.

(SCYX) is the lower-risk stock at 0. 78β versus ICON Public Limited Company's 1. 60β — meaning ICLR is approximately 104% more volatile than SCYX relative to the S&P 500. On balance sheet safety, Simulations Plus, Inc. (SLP) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SLP or SCYX or CRL or ICLR?

By revenue growth (latest reported year), SCYNEXIS, Inc.

(SCYX) is pulling ahead at 449. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: SCYNEXIS, Inc. grew EPS 61. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, SCYX leads at 59. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SLP or SCYX or CRL or ICLR?

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus -81. 7% for Simulations Plus, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICLR leads at 13. 3% versus -89. 3% for SLP. At the gross margin level — before operating expenses — SLP leads at 58. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SLP or SCYX or CRL or ICLR more undervalued right now?

On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10.

5x forward P/E versus 18. 0x for Simulations Plus, Inc. — 7. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SLP: 248. 7% to $56. 00.

08

Which pays a better dividend — SLP or SCYX or CRL or ICLR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SLP or SCYX or CRL or ICLR better for a retirement portfolio?

For long-horizon retirement investors, SCYNEXIS, Inc.

(SCYX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). ICON Public Limited Company (ICLR) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SCYX: -97. 6%, ICLR: +91. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SLP and SCYX and CRL and ICLR?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SLP is a small-cap quality compounder stock; SCYX is a small-cap high-growth stock; CRL is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SLP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 35%
Run This Screen
Stocks Like

SCYX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 904%
Run This Screen
Stocks Like

CRL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Stocks Like

ICLR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SLP and SCYX and CRL and ICLR on the metrics below

Revenue Growth>
%
(SLP: -2.7% · SCYX: 1808.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.